Trials / Completed
CompletedNCT03583944
A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer
Post Marketing Trial (Phase IV) on the Safety, Tolerability And Efficacy of Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate clinical and laboratory safety of eribulin mesylate in treating participants with locally advanced or metastatic breast cancer, who have progressed after at least one regimen of chemotherapy which has included anthracycline and taxane therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eribulin Mesylate | Eribulin mesylate IV infusion. |
Timeline
- Start date
- 2018-03-28
- Primary completion
- 2019-06-28
- Completion
- 2019-06-28
- First posted
- 2018-07-12
- Last updated
- 2019-11-27
Locations
18 sites across 1 country: India
Source: ClinicalTrials.gov record NCT03583944. Inclusion in this directory is not an endorsement.